Company news

Share this article:
Pfizer announced that it has entered into a $15 million dollar collaboration with the University of Pennsylvania School of Medicine. The partnership will include collaborations between Pfizer and the university in the areas of scientific research, clinical development and clinical care and policy. Under the terms of the agreement, Pfizer will pay Penn $15 million over a three-year period, during which time scientists from Pfizer and Penn's School of Medicine will work together on several projects of mutual interest including basic and translational research addressing several therapeutic areas. Project proposals will be solicited and reviewed by a committee with representation from both parties. The initial emphasis of the collaboration will focus on the neurosciences and oncology, but may expand to other areas, Pfizer said in a statement.

Omnicom's digital and CRM-intensive STAR Marketing network launched a healthcare offering. STAR Healthcare will offer “integrated, personalized” direct to patient programs under the guidance of managers to be announced in two unique positions: those of “patient advocate” and “client champion.”

Ketchum launched Well Connected, a “cross-practice health and wellness specialty” aimed at leveraging the shop's expertise in health and wellness, influencer relationships and proprietary research in food and nutrition, healthcare and brand. In addition to research, the practice also offers clients a partnership with the National Senior Games Association and supermarket and branding expert Phil Lempert.  
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.